COHR March 13th Options Begin Trading

At a spot price of $214.01, a $210 put on COHR bids at $19.50, which would set an effective purchase basis of $190.50 if sold-to-open, is ~2% out-of-the-money with a ~60% chance to expire worthless and a reported YieldBoost of 9.29% (78.90% annualized). A $220 call bids at $23.50 for a covered-call write against shares bought at $214.01, representing a 13.78% return to expiration (March 13) if called away, is ~3% out-of-the-money with a ~46% probability to expire worthless and a YieldBoost of 10.98% (93.30% annualized). Implied volatilities are elevated (put IV 84%, call IV 90%) versus a trailing 12-month realized volatility of 73%, highlighting high option premia but also asymmetric upside risk if shares surge.

Analysis

Market structure: The option market is signaling rich short-dated premia on COHR (IV 84–90% vs realized 73%), which benefits option sellers/market-makers collecting yield and investors willing to acquire stock cheaply via cash‑secured puts. Elevated call IV > put IV implies asymmetric demand for upside protection/covering flows (covered‑call sellers) or event-driven bullish positioning; this tightens bid for short-dated calls and increases cost of directional long exposure.

Risk assessment: Short-term (days–weeks) the main risks are earnings/guide surprises and IV spikes — selling premium into earnings can blow up realized P/L; medium-term (months) cyclicality in photonics/laser demand or inventory corrections could drive a 30–50% downside tail. Hidden dependencies include skew shifts if a corporate event (earnings, guidance, M&A chatter) occurs; regulatory or supply‑chain shocks in semicap customers would be low-probability/high-impact.

Trade implications: If you want entry long COHR, selling the Mar13 210 put for 19.50 gives an effective basis of 190.50 (≈11% below spot) with ~60% chance of not being assigned; use cash‑secured puts or a 210/200 bull‑put spread to cap downside. For income, a buy‑stock + sell‑Mar13 220 covered call yields +13.8% to expiry but caps upside; consider size limits (1–3% portfolio) and avoid naked short premium through earnings.

Contrarian angle: The market may be overpricing short-dated directional risk (IV premium >20% over realized) — selling defined‑risk premium is likely profitable absent idiosyncratic news. Conversely, if you assume mean reversion in IV, being long delta via assignment at 190.50 or owning stock with tight downside protection is preferable to outright long options which are bid up and time‑decay negative.

Key Decisions for Investors

• Sell cash‑secured COHR Mar13 210 put at or near current premium (19.50) size to result in max notional ≤2% portfolio exposure; target effective basis 190.50. Only initiate if you are willing to own COHR and IV remains ≥ current level; set a hard risk cut: liquidate/roll if COHR gaps below 170 or IV > 120%.
• Buy COHR shares and sell Mar13 220 covered calls (collect ~23.50) to generate ~13.8% return to expiry; position size 1–3% portfolio for income-oriented sleeve. Close or roll if stock >235 or if an unexpected earnings/guide event is announced before Mar13.
• If you prefer defined risk, structure a Mar13 bull‑put spread: sell 210 put, buy 200 put (10‑point width) to cap max loss to ~$10/share minus net credit; require net credit ≥ $6 before entering. This preserves the ~60% probability profile while limiting tail exposure.
• Do not sell naked short‑dated premium across confirmed earnings or corporate events: verify COHR earnings date within 7 calendar days before any options short; if earnings fall inside the expiry, either widen the spread, move to post‑earnings expiries, or reduce notional by 50%.